Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.31

-0.7%

Jan 29 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (3563)	4/24/2001 1:58:32 PM
From: Jibacoa	Read Replies (1) of 52153

Good news on IMCL today, but the stock remains on a down-trend.<g> NEW YORK--(BW HealthWire)--April 24, 2001-- ImClone Systems Incorporated (Nasdaq: IMCL - news) announced today that the Company has achieved a patient enrollment milestone in its agreement with Merck KGaA for the Company's investigational cancer vaccine candidate BEC2. The milestone, which triggers a $500,000 payment, relates to reaching the halfway mark in study enrollment in its multinational Phase III clinical trial of BEC2 in patients with limited disease small cell lung carcinoma. Merck KGaA is the Company's co-promotion partner for BEC2 in the United States and is co-sponsoring the Phase III clinical trial. BEC2, the Company's lead cancer vaccine candidate, is an investigational anti-idiotypic monoclonal antibody designed to prevent or delay the recurrence of certain types of tumors, such as small cell lung carcinoma. By mimicking the GD3 tumor-associated antigen, BEC2 appears to stimulate a stronger immune response than natural GD3. siliconinvestor.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next